Aug. 5, 2025
— Jeff Ward, Lehigh Valley News Briefs
OraSure Technologies, the Bethlehem-based maker of medical diagnostic tests, has named Anne Messing as its chief commercial officer.
What may be more interesting are the company’s earnings, due shortly after 4 p.m. today (Aug. 5).
Messing has experience with several companies, including Becton Dickinson Biosciences, Quest Diagnostics and Danaher. She “will be responsible for sales, marketing, strategic alliances, and product management.. ” OraSure said Monday.
Not just alliances, but “strategic alliances.” The word strategic is used a lot. Too much. I’m wary of people who have the word “strategic” in their title, although Messing does not.
Shares of OraSure, which sometimes refers to itself as OTI (for OraSure Technologies Inc.), have been bumbling along. At 2:45 p.m. today, the shares (NASDAQ:OSUR) were trading at $3.10.
After a Reuters report a few weeks ago about a supposed bid for the company, nothing more has come out.
OraSure makes in InteliSwab home test for COVID-19 and OraQuick, a test for HIV. It also makes specimen-collection products.
Shares in the company have been declining for years, and last showed consistent strength when OraSure was receiving federal money for COVID contracts and to build a new factory in Bethlehem Township.
What is now known as OraSure was founded in 1988 as SolarCare, a maker of sunscreen towelettes. Transactions and the name change came about later.
Here’s a link to the company statement and below is a cut-and-paste version:
OraSure Appoints Anne Messing as Chief Commercial Officer
August 4, 2025 at 7:05 AM EDT
BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and transforming strategic vision into demonstrable results and sustainable success. In her role at OTI, she will be responsible for Sales, Marketing, Strategic Alliances, and Product Management, and will shape the vision and management of OTI’s product portfolio in its aim to achieve market leadership and drive long-term growth.
Prior to joining OTI, Ms. Messing was Vice President and General Manager of the U.S. Region for Becton Dickinson (BD) Biosciences, spearheading initiatives that outperformed market benchmarks and generated meaningful sales growth from legacy products as well as new product launches. Complementing her 12 years of sales and marketing leadership at BD, she also has deep healthcare experience from prior roles at Danaher, Quest Diagnostics, Siemens Healthcare Diagnostics, and ARUP Laboratories. She spent the early part of her career in the lab as a certified medical technologist and advanced through various levels of management to ultimately lead all the clinical laboratories at Beaumont Hospital in Royal Oak, Michigan. She received her Bachelor of Science in Medical Technology from Northern Michigan University and her Master of Science in Administration from Central Michigan University.
“We are delighted to welcome Anne as our Chief Commercial Officer. I am confident that her deep expertise, motivational leadership, and proven success in delivering results will create exceptional value for our internal and external stakeholders,” said Carrie Eglinton Manner, President and CEO of OTI. “Leveraging her strengths, she will be instrumental in driving the organization forward as we continue to execute our mission to improve access, quality, and value in healthcare through innovative solutions in effortless testing and sample management.”
“I’m excited to step into this transformative chapter with OTI, as the company accelerates its vision for the future and prepares for a wave of impactful and strategic product launches,” Messing said.
About OraSure Technologies
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com.
Lehigh Valley News Briefs 